Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study

BACKGROUND: Sequential treatment of ankylosing spondylitis (AS) that includes tumour necrosis factor-α antagonists (anti-TNF agents) has been applied in most of the Western countries. Existing cost-effectiveness (CE) models almost exclusively presented the incremental CE of anti-TNF agents using a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran-Duy, An, Boonen, Annelies, van de Laar, Mart A. F. J., Severens, Johan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597433/
https://www.ncbi.nlm.nih.gov/pubmed/26451133
http://dx.doi.org/10.1186/s12962-015-0044-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597433/
https://www.ncbi.nlm.nih.gov/pubmed/26451133
http://dx.doi.org/10.1186/s12962-015-0044-x

Ejemplares similares